ENFUEGO THERAPEUTICS, INC.
Pittsboro, NC · Founded 2021 · CIK 0001866961 · Biotech · Private
RNAi-based therapeutic molecules targeting mutant KRAS transcripts using nucleotide modification and ligand conjugation chemistries
- Grants
- $2.8M
- 6 awards
- Sector median: 1
- Raised
- $500K
- 1 Form D · Jun 2021
- 63 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of EFTX-001 to target KRAS mutations in cancer | $224,995 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of EFTX-001 to target KRAS mutations in cancer | $224,995 | |
| Private capital raised | Form D · SEC | $500,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | $275,645 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | $275,645 | |
| Federal grant | Department of Health and Human Services · Phase II · Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | $919,020 | |
| Federal grant | Department of Health and Human Services · Phase II · Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | $919,020 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2600 | Aurora Bio, Inc. | — | — |
| 2601 | NEURODON, LLC | — | $500K |
| 2602 | JumpStart Fertility, Inc. | — | $500K |
| 2603 | ENFUEGO THERAPEUTICS, INC. | — | $500K |
| 2604 | CHAPERONE THERAPEUTICS, INC. | — | $457K |
| 2605 | CONCARLO HOLDINGS, LLC | — | $450K |
| 2606 | GSNO THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Michael DombeckDirector · Executive Officer
- Sue MahonyDirector
- Joe McMahonDirector
- Chad PecotDirector · Executive Officer
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.